<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260509069308N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-14</date_registration>
      <primary_sponsor>University of Guilan</primary_sponsor>
      <public_title>The effect of resistance exercise with blood flow restriction and aerobic exercise order on blood pressure and cardiovascular parameters in overweight and obese postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>The effect of resistance exercise with blood flow restriction and aerobic exercise order on post-exercise hypotension, cardiovascular parameters, plasma Lactate and nitric oxide in overweight and obese postmenopausal women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>12</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93269</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: Participants were individually allocated using simple randomization to different sequences of the three experimental sessions. The session sequences were determined using numbered, opaque, sealed envelopes. The unit of randomization was the individual participant, and no stratified or cluster randomization was used. Allocation concealment was maintained using opaque, sealed envelopes until allocation of each participant.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Healthy women- no disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Resistance exercise with blood flow restriction following aerobic exercise. Intervention 2: Intervention group 2: Aerobic exercise following resistance exercise with blood flow restriction. Intervention 3: Control group: seated rest.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All measured variable data will be made available upon request after anonymization

When:
6 months after publication the results

To whom:
academic researchers and university students

Conditions:
scientific use for improvement and comparison with other studies is permitted

Where to obtain:
Email address for contacting the researcher to request additional information: yasamiinahmadii@gmail.com

How to obtain:
the requester must send the reason for using the documents to the following email address, so that after being reviewed by the researcher, a response will be provided at the earliest opportunity: yasamiinahmadii@gmail.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abuzar Jorbonian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasht, Kilometer 7 of the Rasht–Qazvin Road</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4199613776</zip>
        <telephone>+98 13 3369 0274</telephone>
        <email>jorbonian.a@guilan.ac.ir</email>
        <affiliation>دانشگاه گیلان</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abuzar Jorbonian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasht, Kilometer 7 of the Rasht–Qazvin Road</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4199613776</zip>
        <telephone>+98 13 3369 0274</telephone>
        <email>jorbonian.a@guilan.ac.ir</email>
        <affiliation>University of Guilan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 50–65 years
Being postmenopausal (more than 12 months since the last menstrual period) and not receiving hormone therapy
Body mass index (BMI) between 25 and 34 kg/m²
Physical inactivity and no participation in regular physical activity during the previous 6 months, according to the International Physical Activity Questionnaire (IPAQ)</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Smoking and alcohol consumption
Presence of cardiovascular, pulmonary, or metabolic diseases, or musculoskeletal or joint problems that limit movement, such as knee osteoarthritis or spinal injuries
Diagnosis of hypertension (systolic blood pressure &gt;140 mmHg and/or diastolic blood pressure &gt;90 mmHg)
Use of medications that affect blood pressure and heart rate, such as beta-blockers and calcium antagonists</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Resistance exercise with blood flow restriction following aerobic exercise</i_keyword>
      <i_keyword>Intervention group 2: Aerobic exercise following resistance exercise with blood flow restriction</i_keyword>
      <i_keyword>Control group: seated rest</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure. Timepoint: pre and post intervention, at 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 minutes. Method of measurement: Digital blood pressure monitor (Omron HBP-1120).</prim_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: pre and post intervention, at 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 minutes. Method of measurement: Indirectly, using the formula: DBP + ⅓(SBP − DBP).</prim_outcome>
      <prim_outcome>Double product. Timepoint: pre and post intervention, at 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 minutes. Method of measurement: Indirectly calculated by multiplying heart rate by systolic blood pressure.</prim_outcome>
      <prim_outcome>Heart rate variability. Timepoint: pre and post intervention, at 0-5، 5-10، 15-20، 25-30، 35-40، 45-50، 55-60، 65-70، 75-80، 85-90 minutes. Method of measurement: Polar H10 heart rate monitor belt.</prim_outcome>
      <prim_outcome>Plasma lactate. Timepoint: Pre and 4 minutes post intervention. Method of measurement: biochemical kit based on the enzymatic method.</prim_outcome>
      <prim_outcome>Plasma nitric oxide. Timepoint: Pre and 4 minutes post intervention. Method of measurement: NatrixTM kit based on the Griess method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Guilan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-25</approval_date>
        <contact_name>Ethics committee of guilan university of medical sciences</contact_name>
        <contact_address>Shahrak-e Qods (Gharb), between Felamk-e Jonoubi and Zarafshan, Simaye Iran Street, Central Headquarters of the Ministry of Health and Medical Education Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
